Non-neutralizing antibodies in prevention of HIV infection (Q38058120)

27 August 2017

Non-neutralizing antibodies in prevention of HIV infection (English)

1 reference

27 August 2017

prevention of HIV/AIDS

0 references

1 reference

Harriet L Robinson

1

0 references

language of work or name

English

0 references

publication date

6 November 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

1 reference

27 August 2017

13

1 reference

27 August 2017

2

1 reference

27 August 2017

197-207

1 reference

Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

FcgammaRIIa genotype predicts progression of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Humoral immunity to HIV-1: neutralization and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Fc receptor but not complement binding is important in antibody protection against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.743527

10.1517/14712598.2012.743527

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23130709